Skip to main content

Matilde Lleonart Pajarin

I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.

Institutions of which they are part

Head of group
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Vall Hebron Institut de Recerca

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Head and Neck Cancer: Biomedical Research Cancer Stem cells
Vall Hebron Institut de Recerca

I am group leader of "Biomedical Research in Cancer Stem Cells" at VHIR. I arrived at VHIR 21 years ago after having worked in different prestigious international research centers: World Health Organization (WHO) at the International Agency for Research on Cancer (IARC) (Lyon, France), the Wolfson Institute for Biomedical Research (WIBR) in London and the Queen´s Mary University of London.

My Research Group was recognized as an Emerging Research Group in 2009 by the Generalitat de Catalunya and later in 2014 as a Consolidated Research Group.
Throughout my career I have been involved in cancer research from a more molecular point of view correlating key mutations in oncogenes and tumor suppressor genes with anatomical, pathological and clinical features of patients' tumors and also through cell culture studies to determine important key cell signaling pathways in tumorigenesis.
Currently, the main lines of research of my Research Group focus on the identification and characterization of biological mechanisms in resistant cancer cells, including cancer stem cells, to unravel the pathways responsible for their resistance in breast, lung and head and neck cancer models.
In addition, we are particularly focused on identifying molecular targets in resistant cancer cells and cancer stem cells affecting particularly aggressive tumors. The aim is to attack them pharmacologically in order to propose new cancer therapies: new drugs and/or drug combinations to combat resistant tumors in mouse models.

Projects

Identificación y caracterización de nuevos genes que inmortalicen células primarias y su papel en tumores humanos

IP: Matilde Lleonart Pajarin
Collaborators: Santiago Ramon y Cajal Agüeras, Carmela Iglesias i Felip, Javier Hernandez Losa
Funding agency: Instituto de Salud Carlos III
Funding: 94300
Reference: PI040530
Duration: 01/01/2005 - 30/08/2008

Búsqueda de genes existentes en células embrionarias murinas que estén implicados en la inmortalización

IP: Santiago Ramon y Cajal Agüeras
Collaborators: Matilde Lleonart Pajarin
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: CP03/00101
Duration: 01/03/2004 - 28/02/2010

Búsqueda de genes existentes en células embrionarias murinas que estén implicados en la inmortalización

IP: Matilde Lleonart Pajarin
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 42070
Reference: CP03/00101
Duration: 01/03/2004 - 28/02/2007

Related news

The sessions were aimed at establishing new collaborations to advance the prevention and treatment of this type of tumour.

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

Related professionals

Josep Castellví Vives

Josep Castellví Vives

Translational Molecular Pathology
Read more
Miquel Raspall Chaure

Miquel Raspall Chaure

Pediatric Neurology
Read more
Mireia Andres Villarreal

Mireia Andres Villarreal

Predoctoral researcher
Cardiovascular Diseases
Read more
Xavier Buxo Masip

Xavier Buxo Masip

Predoctoral researcher
Research Group of Physical Medicine and Rehabilitation
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.